GleamWall
中文EN

MXCT MAXCYTE, INC.

Services-Commercial Physical & Biological Research · Nasdaq · SEC CIK 1287098 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-0.1%
TTM net income YoY38.7%
TTM EPS YoY39.5%
Revenue 3-yr CAGR-3.3%
Net income 3-yr CAGR—

Margins

Gross margin81.0%
Operating margin-98.0%
Net margin-81.4%
FCF margin-62.4%
EBITDA margin-86.5%

Returns

ROE-16.9%
ROA-14.1%
ROIC (approx.)-17.5%
Asset turnover0.17x

Leverage & solvency

Liabilities / assets17.3%
Debt / equity0.00x
Current ratio7.83x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-3.5%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$10.15M$7.27M$9.65M$7.30M$6.83M$8.51M$10.39M$8.69M
Cost of revenue$1.68M$1.68M$1.57M$1.61M$1.60M$1.52M$1.50M$2.28M
Gross profit$8.47M$5.60M$8.08M$5.69M$5.23M$6.99M$8.89M$6.41M
R&D expense$2.87M$4.25M$3.86M$3.33M$5.32M$6.27M$5.90M$4.61M
SG&A expense$6.55M$7.26M$5.97M$5.48M$6.03M$8.08M$8.53M$7.21M
Operating income-$6.04M-$10.23M-$6.18M-$11.23M-$14.15M-$14.23M-$12.29M-$12.90M
Pretax income-$4.76M-$8.87M-$4.75M-$9.60M-$12.42M-$12.36M-$10.26M-$10.60M
Net income-$4.76M-$8.87M-$4.75M-$9.60M-$12.42M-$12.36M-$10.26M-$10.60M
EBITDA-$5.17M-$9.28M-$5.14M-$10.15M-$13.11M-$13.15M-$11.20M-$11.84M
EPS (basic)-0.05-0.08-0.04—-0.12-0.12-0.10—
EPS (diluted)-0.05-0.08-0.04—-0.12-0.12-0.10—
Weighted avg. shares (diluted)103.54M106.82M106.88M—106.61M106.40M105.95M—
Balance sheet
Cash & equivalents$13.37M$15.04M$14.56M$20.07M$12.97M$15.22M$23.39M$27.88M
Short-term investments$87.91M$90.65M$92.30M$82.98M$92.75M$111.34M$114.89M$126.60M
Receivables$12.05M$3.92M$4.25M$3.50M$8.31M$5.75M$5.53M$4.68M
Inventory$7.38M$7.80M$7.63M$7.55M$7.61M$7.93M$8.27M$8.91M
Current assets$124.67M$121.27M$122.94M$118.37M$124.64M$143.22M$155.75M$171.68M
PP&E, net$14.34M$14.90M$16.64M$17.53M$18.62M$19.40M$19.92M$19.71M
Goodwill————$3.55M$3.75M$3.92M—
Intangibles$749,000$766,000$783,000$650,000$667,000$638,000$650,000—
Total assets$182.48M$184.67M$194.47M$202.51M$213.48M$219.75M$229.96M$239.47M
Current liabilities$15.92M$9.89M$10.21M$14.27M$16.10M$11.55M$12.73M$15.78M
Total liabilities$31.55M$25.92M$26.59M$31.02M$33.20M$29.03M$30.55M$33.22M
Shareholders' equity$150.93M$158.75M$167.89M$171.49M$180.28M$190.72M$199.41M$206.25M
Shares outstanding103.23M106.13M107.12M106.79M106.64M106.59M106.31M105.71M
Cash flow statement
Operating cash flow-$5.51M-$4.66M-$8.17M-$2.69M-$7.46M-$9.85M-$14.41M-$7.82M
Capital expenditure$59,000$62,000$72,000$231,000$300,000$584,000$653,000$147,000
Free cash flow-$5.57M-$4.72M-$8.24M-$2.92M-$7.76M-$10.44M-$15.06M-$7.97M
Investing cash flow$7.86M$6.57M$2.66M$9.68M$5.19M$1.54M$9.53M-$1.67M
Financing cash flow-$4.02M-$1.42M$5,000$105,000$14,000$154,000$383,000$412,000
Depreciation & amortization$868,000$953,000$1.05M$1.07M$1.04M$1.08M$1.10M$1.06M
Stock-based compensation$963,000$1.16M$1.14M$706,000$1.95M$3.51M$3.04M$3.13M
Share buybacks$4.02M———————

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.